After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the Morris County site last year, filings with the New Jersey Department of Labor ...

Last year, Novartis agreed to buy U.S.-based Mariana Oncology for $1 billion upfront to expand its portfolio of the drugs, ...

Novartis’s Fabhalta submission in C3G was ... a twice-weekly infusion from Apellis Pharmaceuticals that blocks the complement system protein C3. The two drugs could also become competitors ...

The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ (NOVN: VX) oral Fabhalta (iptacopan) for ...

The Swiss pharma giant – which has its U.S. headquarters in East Hanover – said it aims to encourage football fans to "proactively manage their health." ...